Filter Results:
(6)
Show Results For
- All HBS Web (11)
- Faculty Publications (3)
Show Results For
- All HBS Web (11)
- Faculty Publications (3)
Page 1 of 6
Results
Sort by
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- January 2014
- Teaching Plan
MedImmune Ventures
By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details
Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States
Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- 14 Dec 2020
- Research & Ideas
What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?
saying; “Look, everyone should understand that this is risky.” And yet, as I mentioned above, I don’t think this is going to happen. This AstraZeneca hiccup isn’t going to be the last one. I can all but assure you of that. Once we start... View Details
- 28 Oct 2014
- First Look
First Look: October 28
Business School Case 515-007 Pfizer and AstraZeneca: Marketing an Acquisition (A) In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for... View Details
Keywords: Carmen Nobel
- 25 May 2016
- Research & Ideas
How Consumers and Businesses are Reshaping Public Health
commercialization of important new drugs to the detriment of consumers. Interestingly, though, at public hearings, the AstraZeneca chief executive championed the interests of patients in opposing the proposed merger. Consumers worldwide... View Details